Products

For the treatment of:

• Hyperlipidemia and mixed dyslipidemia as adjunctive therapy to diet to reduce elevated Total-C, LDL-C,
  ApoB, nonHDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Lipid altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate.
• Pediatric patients 10 to 17 years of age with heterozygous familal hypercholesterolemia (HeFH) as adjunct to diet to reduce Total-C, LDL-C and ApoB levels in adolescent boys and girls, who are at least one year postmenarche, 10-17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C greater than 190 mg/dL or greater than 160 mg/dL and there is a positive family his tory of premature cardiovascular disease (CVD) or two or more other CVD risk factors.